PML/RARalpha Fusion Protein Transactivates the Tissue Factor Promoter Through a GAGC-containing Element Without Direct DNA Association
Overview
Authors
Affiliations
A severe coagulopathy is a life-threatening complication of acute promyelocytic leukemia (APL) and is ascribable mainly to the excessive levels of tissue factor (TF) in APL cells regulated in response to the promyelocytic leukemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein. The underlying molecular mechanisms for this regulation remain ill-defined. With U937-PR9 cell lines stably expressing luciferase reporter gene under the control of different mutants of the TF promoter, both luciferase and ChIP data allowed the localization of the PML/RARalpha-responsive sequence in a previously undefined region of the TF promoter at position -230 to -242 devoid of known mammalian transcription factor binding sites. Within this sequence a GAGC motif (-235 to -238) was shown to be crucial because deletion or mutation of these nucleotides impaired both PML/RARalpha interaction and promoter transactivation. However, EMSA results showed that PML/RARalpha did not bind to DNA probes encompassing the -230 to -242 sequences, precluding a direct DNA association. Mutational experiments further suggest that the activator protein 1 (AP-1) sites of the TF promoter are dispensable for PML/RARalpha regulation. This study shows that PML/RARalpha transactivates the TF promoter through an indirect interaction with an element composed of a GAGC motif and the flanking nucleotides, independent of AP-1 binding.
Thrombosis in Myeloid Malignancies: From CHIP to AML.
Borsellino B, Bravo-Perez C, Visconte V, Guarnera L Cardiovasc Hematol Disord Drug Targets. 2024; 24(1):2-12.
PMID: 38879768 DOI: 10.2174/011871529X307253240530060107.
A machine learning model identifies M3-like subtype in AML based on PML/RARα targets.
Shao T, Li J, Su M, Yang C, Ma Y, Lv C iScience. 2024; 27(2):108947.
PMID: 38322990 PMC: 10844831. DOI: 10.1016/j.isci.2024.108947.
Hermsen J, Hambley B Cancers (Basel). 2023; 15(13).
PMID: 37444587 PMC: 10340352. DOI: 10.3390/cancers15133477.
Pei Y, Shi M, Song J, Niu X, Wei S, Dou L Cancer Manag Res. 2021; 13:4135-4146.
PMID: 34045900 PMC: 8149285. DOI: 10.2147/CMAR.S309138.
Tan Y, Wang X, Song H, Zhang Y, Zhang R, Li S Blood. 2020; 137(11):1503-1516.
PMID: 32854112 PMC: 7976511. DOI: 10.1182/blood.2020005698.